Skip to main content
. 2022 Oct 8;42(11):977–985. doi: 10.1007/s40261-022-01209-8

Table 2.

End-of-study levels of different biomarkers in the LoDoCo2 subpopulation

Biomarker Colchicine [n = 895] Placebo [n = 881] p value ULN
Renal function
 Creatinine [µmol/L] 82.7 (74.0–94.4) 82.6 (73.5–94.0) 0.99 110
 Blood urea nitrogen [mmol/L] 6.3 (5.3–7.5) 6.3 (5.3–7.5) 0.96 30
 Estimated glomerular filtration rate [mL/min/1.73 m2] 79.3 (15.3) 79.6 (15.4) 0.76 120
Liver function
 Alanine aminotransferase [U/L] 30.0 (22.0–40.0) 26.0 (19.0–34.0) < 0.01 40
 γ-Glutamyl transferase [U/L] 30.0 (21.0–48.0) 30.0 (21.0–44.0) 0.31 60
 Bilirubin [µmol/L] 9.5 (7.0–12.2) 9.2 (7.2–12.0) 0.73 20
 Albumin [g/L] 43.0 (2.4) 42.6 (2.5) < 0.01 50
Creatine kinase
 Creatine kinase [U/L] 123.0 (84.0–184.0) 110.0 (77.0–164.0) < 0.01 190

Data are expressed as mean (SD) or median (25th–75th percentile). p values were calculated using an independent samples t test or Mann–Whitney U test where applicable

SD standard deviation, ULN upper limit of normal, U unit, LoDoCo2 Low-Dose Colchicine-2 trial